YALE PHYLLIS R 4

What Happened

• Phyllis R. Yale, a director of Bristol Myers Squibb (BMY), received an award of 607.428 deferred share units (DSUs) on 2026-06-30. The units were valued at $57.62 each, for a total grant value of $35,000. This was an award/grant (derivative) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-30; Filing date: 2026-07-02 (appears timely for a Form 4 reporting a 6/30 transaction).
• Award type/code: A (Grant/award; derivative DSUs).
• Amount and price: 607.428 DSUs @ $57.62 per share, total $35,000.
• Shares owned after transaction: Not specified in the provided excerpt.
• Footnotes:
  • F1: Each DSU will convert into a share of common stock upon settlement; DSUs become settleable when the director leaves the board or at a previously specified future date.
  • F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
• No indication of a 10b5-1 plan, sale, gift, tax withholding, or late filing in the excerpt provided.

Context

• This is a routine director compensation award (deferred share units). DSUs are a form of deferred pay that convert into actual shares at a later settlement date, so this does not represent an immediate purchase or sale and does not necessarily signal a change in the director’s view of the company. Purchases by insiders can be more indicative of bullish sentiment; grants like this are common for non-employee directors as part of compensation.